Expression of @entity460 sensing receptor and @entity5962 correlated with XXXX .

@entity1631 @entity1 @entity5 @entity5962 @entity3 @entity460 @entity2220
BACKGROUND: It has been reported that the @entity460 sensing receptor ( @entity1631 ), a widely expressed G protein-coupled receptor, can stimulate cell differentiation and proliferation. However, in @entity5 , loss of @entity1631 expression has been associated with tumorigenesis, @entity3 , and progression. Recent studies have indicated that the @entity1631 could promote the expression of @entity5962 , which was considered a @entity5 suppressor. However, in @entity1 @entity2220 , the importance of the @entity1631 and @entity5962 has not been sufficiently investigated. METHODS: Expression levels of @entity1631 and @entity5962 in paraffin sections from 117 resected @entity2220 @entity1 were evaluated by immunohistochemistry. We analyzed the correlation between our target proteins and clinical variables. Clinical significance was analyzed by multivariate Cox regression analysis, Kaplan-Meier curve, and log-rank test. RESULTS: Expression of the @entity1631 in @entity2220 tissue was significantly lower than in the normal sample (P = 0.003). Kendall tau-b analysis showed that, in a @entity2220 sample, the expression of @entity1631 positively correlated with a high level of @entity5962 (P < 0.001). @entity2220 @entity1 with a strong expression of @entity1631 (P = 0.034) or @entity5962 (P = 0.001) had longer overall survival. Multivariate Cox proportional hazards model analysis showed that the combined marker was an independent prognostic indicator of overall survival (hazard ratio = 0.440, confidence interval = 0.249-0.779, P = 0.005). CONCLUSIONS: We identified the @entity1631 as a new prognostic biomarker in @entity2220 . These results also suggested that the @entity1631 may become a new therapeutic @entity2220 .
